GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Dynavax Technologies Corp (NAS:DVAX) » Definitions » Inventory-to-Revenue

Dynavax Technologies (Dynavax Technologies) Inventory-to-Revenue : 0.92 (As of Dec. 2023)


View and export this data going back to 2004. Start your Free Trial

What is Dynavax Technologies Inventory-to-Revenue?

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Dynavax Technologies's Average Total Inventories for the quarter that ended in Dec. 2023 was $51.4 Mil. Dynavax Technologies's Revenue for the three months ended in Dec. 2023 was $55.6 Mil. Dynavax Technologies's Inventory-to-Revenue for the quarter that ended in Dec. 2023 was 0.92.

Dynavax Technologies's Inventory-to-Revenue for the quarter that ended in Dec. 2023 increased from Sep. 2023 (0.74) to Sep. 2023 (0.92)

An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:

1. investment in inventory is growing more rapidly than revenue
2. revenue are dropping
No matter which situation is causing the problem, an increase in the Inventory-to-Revenue may signal an oncoming cash flow problem.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Dynavax Technologies's Days Inventory for the three months ended in Dec. 2023 was 539.28.

Inventory Turnover measures how fast the company turns over its inventory within a year. Dynavax Technologies's Inventory Turnover for the quarter that ended in Dec. 2023 was 0.17.


Dynavax Technologies Inventory-to-Revenue Historical Data

The historical data trend for Dynavax Technologies's Inventory-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dynavax Technologies Inventory-to-Revenue Chart

Dynavax Technologies Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Inventory-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.86 1.13 0.14 0.08 0.24

Dynavax Technologies Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Inventory-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.44 1.25 0.92 0.74 0.92

Competitive Comparison of Dynavax Technologies's Inventory-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Dynavax Technologies's Inventory-to-Revenue, along with its competitors' market caps and Inventory-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Dynavax Technologies's Inventory-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Dynavax Technologies's Inventory-to-Revenue distribution charts can be found below:

* The bar in red indicates where Dynavax Technologies's Inventory-to-Revenue falls into.



Dynavax Technologies Inventory-to-Revenue Calculation

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Dynavax Technologies's Inventory-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Inventory-to-Revenue (A: Dec. 2023 )
=Average Total Inventories / Revenue
=( (Total Inventories (A: Dec. 2022 ) + Total Inventories (A: Dec. 2023 )) / count ) / Revenue (A: Dec. 2023 )
=( (59.446 + 53.29) / 2 ) / 232.284
=56.368 / 232.284
=0.24

Dynavax Technologies's Inventory-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Inventory-to-Revenue (Q: Dec. 2023 )
=Average Total Inventories / Revenue
=( (Total Inventories (Q: Sep. 2023 ) + Total Inventories (Q: Dec. 2023 )) / count ) / Revenue (Q: Dec. 2023 )
=( (49.412 + 53.29) / 2 ) / 55.596
=51.351 / 55.596
=0.92

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Dynavax Technologies  (NAS:DVAX) Inventory-to-Revenue Explanation

An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:

1. investment in inventory is growing more rapidly than revenue
2. revenue are dropping
No matter which situation is causing the problem, an increase in the Inventory-to-Revenue may signal an oncoming cash flow problem.

Likewise, a decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:

1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.

More Related Terms:

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Dynavax Technologies's Days Inventory for the three months ended in Dec. 2023 is calculated as:

Days Inventory=Average Total Inventories (Q: Dec. 2023 )/Cost of Goods Sold (Q: Dec. 2023 )*Days in Period
=51.351/8.689*365 / 4
=539.28

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Dynavax Technologies's Inventory Turnover for the quarter that ended in Dec. 2023 is calculated as

Inventory Turnover=Cost of Goods Sold (Q: Dec. 2023 ) / Average Total Inventories (Q: Dec. 2023 )
=8.689 / 51.351
=0.17

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Dynavax Technologies Inventory-to-Revenue Related Terms

Thank you for viewing the detailed overview of Dynavax Technologies's Inventory-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Dynavax Technologies (Dynavax Technologies) Business Description

Traded in Other Exchanges
Address
2100 Powell Street, Suite 900, Emeryville, CA, USA, 94608
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.
Executives
Robert Janssen officer: Chief Medical Officer and VP C/O DYNAVAX TECHNOLOGIES, 2929 SEVENTH STREET, SUITE 100, BERKELEY CA 94710
David F Novack officer: Senior Vice President 39 YORKSHIRE DR, OAKLAND CA 94618
Hack Andrew A. F. director 300 THIRD STREET, FIRST FLOOR, CAMBRIDGE MA 02142
Justin Burgess officer: Principal Accounting Officer C/O DYNAVAX TECHNOLOGIES CORPORATION, 2100 POWELL STREET, SUITE 1900, EMERYVILLE CA 94608
Ryan Spencer officer: Co-President and Senior VP C/O DYNAVAX TECHNOLOGIES CORPORATION, 2929 SEVENTH STREET, SUITE 100, BERKELEY CA 94710-2753
Francis Cano director 11 ACORN LANE, LOS ALTOS CA 94022
Elaine D Sun director 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121
Scott Dunseth Myers director C/O CASCADIAN THERAPEUTICS, INC., 3101 WESTERN AVE., SUITE 600, SEATTLE WA 98121
Kelly Macdonald officer: SVP and CFO 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Peter R. Paradiso director C/O DYNAVAX TECHNOLOGIES CORPORATION, 2100 POWELL STREET, SUITE 900, EMERYVILLE CA 94608
Julia Marie Eastland director C/O CASCADIAN THERAPEUTICS, INC., 3101 WESTERN AVE., SUITE 600, SEATTLE WA 98121
Brent Macgregor director C/O DYNAVAX TECHNOLOGIES CORPORATION, 2100 POWELL STREET, SUITE 900, EMERYVILLE CA 94608
Peggy V Phillips director C/O DYNAVAX TECHNOLOGIES CORPORATION, 2929 SEVENTH STREET, SUITE 100, BERKELEY CA 94710
Robert Coffman officer: Chief Science Officer and VP C/O DYNAVAX TECHNOLOGIES CORP, 2929 SEVENTH ST STE 100, BERKELEY CA 94710
Michael S Ostrach officer: VP, CBO, and General Counsel 1300 SEAPORT BOULEVARD, REDWOOD CITY CA 94063